Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Investigating the role of POLR3 in oligodendrocyte-lineage development and myelination in vivo: Translational disease models and proof-of-concept for using in vivo gene therapy to treat POLR3-related Hypomyelinating Leukodystrophy.

FY 2019-20

Summary
Leukodystrophies are a group of rare genetic diseases affecting brain development that collectively occur in 1:7500 individuals. Children with leukodystrophy grow normally until they develop neurological signs, especially movement problems. Based on medical imaging, we know that leukodystrophies result from genetic alterations leading to abnormalities in the white matter of the brain. The main component of white matter called myelin is necessary for the correct function of the nervous system. Myelin is normally produced by a specialized cell lineage that itself grows and matures along with the brain. In different leukodystrophies, myelin may develop incorrectly or disappear. However, if myelin does not develop, it is called a hypomyelinating leukodystrophy (HLD). Functional decline is often drastic and fatal, and unfortunately no treatment is available for children with HLD. We discovered the recessive mutations that characterize patients with the most common HLD called RNA Polymerase III-related Hypomyelinating Leukodystrophy (POLR3-HLD). Patients inherit two affected copies of POLR3 genes leading to hypomyelination and decreased POLR3 expression and function, whereas carriers have one affected gene copy and no disease. The fact that hypomyelination is so pronounced in patients indicates an early deficit in the lineage of cells that produce myelin. These observations have led us to hypothesize that POLR3 gene defects lead to deficits in maturation and function of the myelin-producing cell lineage. This proposal aims to address two fundamental research problems for the first time. 1) We propose to implement an animal model to directly study the role of POLR3 in the maturation and function of myelinating cells during myelination in vivo. 2) In order to remediate POLR3-related hypomyelination, we propose to design and validate gene therapy techniques to target the myelinating cell lineage, which may also prove useful for other diseases affecting white matter.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
415860
Name
Michell-Robinson Mackenzie A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Investigating the role of POLR3 in oligodendrocyte-lineage development and myelination in vivo: Translational disease models and proof-of-concept for using in vivo gene therapy to treat POLR3-related Hypomyelinating Leukodystrophy.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Adeno-Associated Virus; Animal Models Of Cns Disease; In Vitro Models Of Cns Disease; Lineage Development; Myelination; Neurodegenerative Disease; Neurodevelopment; Pediatric Disease; Translational Research; White Matter Disease
Abstract
Leukodystrophies are a group of rare genetic diseases affecting brain development that collectively occur in 1:7500 individuals. Children with leukodystrophy grow normally until they develop neurological signs, especially movement problems. Based on medical imaging, we know that leukodystrophies result from genetic alterations leading to abnormalities in the white matter of the brain. The main component of white matter called myelin is necessary for the correct function of the nervous system. Myelin is normally produced by a specialized cell lineage that itself grows and matures along with the brain. In different leukodystrophies, myelin may develop incorrectly or disappear. However, if myelin does not develop, it is called a hypomyelinating leukodystrophy (HLD). Functional decline is often drastic and fatal, and unfortunately no treatment is available for children with HLD. We discovered the recessive mutations that characterize patients with the most common HLD called RNA Polymerase III-related Hypomyelinating Leukodystrophy (POLR3-HLD). Patients inherit two affected copies of POLR3 genes leading to hypomyelination and decreased POLR3 expression and function, whereas carriers have one affected gene copy and no disease. The fact that hypomyelination is so pronounced in patients indicates an early deficit in the lineage of cells that produce myelin. These observations have led us to hypothesize that POLR3 gene defects lead to deficits in maturation and function of the myelin-producing cell lineage. This proposal aims to address two fundamental research problems for the first time. 1) We propose to implement an animal model to directly study the role of POLR3 in the maturation and function of myelinating cells during myelination in vivo. 2) In order to remediate POLR3-related hypomyelination, we propose to design and validate gene therapy techniques to target the myelinating cell lineage, which may also prove useful for other diseases affecting white matter.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Michell-Robinson, Mackenzie A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McGill University - $150,000 Grant (2019-20) | Canada Spends